Skip to content

A Weidenauer

2 papers in the library · publishing 2026

Papers

Sort Most recent Most cited

551. Esketamine in neuropsychiatric long COVID: a retrospective analysis

The International Journal of Neuropsychopharmacology September 1, 2026 N Hartman, D Ivkic, M C Dorczok et al.

Abstract Background Neuropsychiatric manifestations of Long COVID (LC) frequently include post-exertional malaise (Cheng et al., 2025), fatigue, cognitive dysfunction and impairment, sleep disturbances, post-traumatic stress, autonomic dysregulation, pain, inner tension, psychomotor retardation, aberrations in appetite and weight (Badenoch et al., 2022; O'Mahoney et al., 2025), showing...

Ketamine for negative and depressive symptoms in schizophrenia: the evidence so far.

Frontiers in Psychiatry 2026 C M Diendorfer, C Bum, A Weidenauer et al.

Schizophrenia (SCZ) is a severe psychiatric condition characterized by positive symptoms such as hallucinations or delusions, as well as negative symptoms such as apathy, anhedonia and avolition. Given their chronic nature and limited response to current treatments, managing negative symptoms is a significant challenge for healthcare providers. Furthermore, many individuals with SCZ suffer from...